4 results on '"Christel Saint-Raymond"'
Number of results to display per page
Search Results
2. Direct molecular diagnosis of aspergillosis and CYP51A profiling from respiratory samples of French patients
- Author
-
Yanan Zhao, Cécile Garnaud, Marie-Pierre Brenier-Pinchart, Anne Thiébaut-Bertrand, Christel Saint-Raymond, Boubou Camara, Rebecca Hamidfar-Roy, Odile Cognet, Danièle Maubon, Muriel Cornet, and David S Perlin
- Subjects
Aspergillus fumigatus ,Molecular diagnostics ,Azole resistance ,Respiratory samples ,CYP51A ,French patients ,Microbiology ,QR1-502 - Abstract
Background: Microbiological diagnosis of aspergillosis and triazole resistance is limited by poor culture yield. To better estimate this shortcoming, we compared culture and molecular detection of A. fumigatus in respiratory samples from French patients at risk for aspergillosis. Methods: A total of 97 respiratory samples including bronchoalveolar lavages (BAL), bronchial aspirates (BA), tracheal aspirates, sputa, pleural fluids, and lung biopsy were collected from 33 patients having invasive aspergillosis (n=12), chronic pulmonary aspergillosis (n=3), allergic bronchopulmonary aspergillosis (n=7) or colonization (n=11) and 28 controls. Each specimen was evaluated by culture, pan-Aspergillus qPCR, and CYP51A PCR and sequencing. Results: One A. flavus and 19 A. fumigatus with one multiazole resistant strain (5.3%) were cultured from 20 samples. Culture positivity was 62.5%, 75%, 42.9%, and 15.8% in ABPA, CPA, IA and colonized patients, respectively. Aspergillus detection rate was significantly higher by pan-Aspergillus qPCR than by culture in IA (90.5% vs 42.9%; P
- Published
- 2016
- Full Text
- View/download PDF
3. COVID-19 in Lung Transplant Recipients
- Author
-
Nicolas Carlier, Adrien Tissot, Martine Reynaud-Gaubert, Benjamin Renaud-Picard, Xavier Demant, Sacha Mussot, Ana Nieves, Christel Saint Raymond, Sandrine Hirschi, Philippine Eloy, Aurélie Le Borgne, Jonathan Messika, Marie-Pierre Debray, Véronique Boussaud, Agathe Sénéchal, Jean-François Mornex, Loïc Falque, Jérôme Le Pavec, L. Beaumont, Hervé Mal, Jacques Jougon, Antoine Roux, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), INSERM UMR1152, Service de Pneumologie et Transplantation Pulmomaire, Hôpital Bichat - Claude Bernard, Assistance Publique - Hôpitaux de Paris (AP-HP), Département d’Epidémiologie et Recherche Clinique [AP-HP Hôpital Bichat - Claude Bernard] (CIC‑EC 1425), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Les Hôpitaux Universitaires de Strasbourg (HUS), Aix Marseille Université (AMU), Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France, «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, Le Plessis-Robinson, hôpital Louis-Pradel, CHU de Lyon, 69500 Bron, France., Centre Hospitalier Universitaire [Grenoble] (CHU), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Foch [Suresnes], Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), CHU Toulouse [Toulouse], École pratique des hautes études (EPHE), and HAL UVSQ, Équipe
- Subjects
Adult ,Male ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,030230 surgery ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Internal medicine ,Humans ,Medicine ,Lung transplantation ,Letters to the Editor ,Survival rate ,Retrospective Studies ,Univariate analysis ,Transplantation ,SARS-CoV-2 ,business.industry ,COVID-19 ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Intensive care unit ,Transplant Recipients ,3. Good health ,[SDV] Life Sciences [q-bio] ,Intensive Care Units ,Pneumonia ,Cohort ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Female ,030211 gastroenterology & hepatology ,business ,Immunosuppressive Agents ,Lung Transplantation ,Cohort study - Abstract
International audience; BACKGROUND: A concern about the susceptibility of immunocompromised patients to the worldwide pandemic of coronavirus disease 2019 (COVID-19) has been raised. We aimed at describing COVID-19 infections in the French cohort of lung transplant (LT) patients. METHODS: Multicenter nationwide cohort study of all LT recipients with COVID-19 diagnosed from March 1 to May 19, 2020. Recipient main characteristics and their management were retrieved. Hospitalization characteristics, occurrence of complications and survival were analyzed. RESULTS: Thirty-five LT patients with a COVID-19 infection were included. Median age was 50.4 (40.6-62.9) years, 16 (45.7%) were female, and 80% were double-LT recipients. Infection was community-acquired in 25 (71.4%). Thirty-one (88.6%) required hospitalization, including 13 (41.9%) in the intensive care unit. The main symptoms of COVID-19 were fever, cough, and diarrhea, present in 71.4%, 54.3%, and 31.4% of cases, respectively. Extension of pneumonia on chest CT was moderate to severe in 51.4% of cases. Among the 13 critically ill patients, 7 (53.9%) received invasive mechanical ventilation. Thrombotic events occurred in 4 patients. Overall survival rate was 85.7% after a median follow-up of 50 days (41.0-56.5). Four of 5 nonsurvivors had had bronchial complications or intensification of immunosuppression in the previous weeks. On univariate analysis, overweight was significantly associated with risk of death (odds ratio, 16.0; 95% confidence interval, 1.5-170.6; P = 0.02). CONCLUSIONS: For the 35 LT recipients with COVID-19, the presentation was severe, requiring hospitalization in most cases, with a survival rate of 85.7%. Copyright
- Published
- 2020
- Full Text
- View/download PDF
4. Relative impact of human leukocyte antigen mismatching and graft ischemic time after lung transplantation
- Author
-
J.-F. Velly, B. Philippe, Marc Stern, Martine Reynaud-Gaubert, Christel Saint Raymond, Jean-François Mornex, Gabriel Thabut, Michel Fournier, Olivier Brugière, Michèle Bertocchi, Pascal Thomas, Yves Castier, Christophe Pison, Claire Dromer, Giuseppina Biondi, Gaëlle Dauriat, Caroline Suberbielle, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Sainte Marguerite, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte Marguerite, CHU Grenoble, Rétrovirus et Pathologie Comparée (RPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL), Hôpital Louis Pradel, Hospices Civils de Lyon (HCL), Hôpital du Haut-L'Evêque, and Hôpital Foch [Suresnes]
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Multivariate analysis ,Time Factors ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Bronchiolitis obliterans ,Human leukocyte antigen ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,HLA Antigens ,Ischemia ,BRONCHIOLITIS-OBLITERANS-SYNDROME ,Internal medicine ,Medicine ,Lung transplantation ,Humans ,Survival rate ,Bronchiolitis Obliterans ,Transplantation ,business.industry ,Histocompatibility Testing ,Hazard ratio ,Graft Survival ,Middle Aged ,medicine.disease ,Confidence interval ,3. Good health ,TIME ,HLA ,030228 respiratory system ,REGISTRY ,Immunology ,Cardiology ,RISK-FACTORS ,KIDNEYS ,SURVIVAL ,Surgery ,Female ,Cardiology and Cardiovascular Medicine ,business ,Lung Transplantation - Abstract
International audience; Background: Recent data strongly suggest that human leukocyte antigen (HLA) mismatching has a negative impact on development of bronchiolitis obliterans syndrome (BOS) and survival after lung transplantation (LTx). Because HLA matching is sometimes achieved by extending ischemic time in other sotid-organ transplantation models and ischemic time is a risk factor per se for death after LTx, we sought to compare the theoretical benefit of HLA matching with the negative impact of lengthened ischemic time. Methods: In this collaborative study we compared the relative impact of HLA mismatching and ischemic time on BOS and survival in 182 LTx recipients. Results: Using multivariate analyses, we observed a lower incidence of BOS (hazard ratio [HR] = 1.70, 95% confidence interval [CI]: 1.1 to 2.7, p = 0.03) and enhanced survival (HR = 1.91, 95% CI: 1.24 to 2.92, p = 0.01) in patients with zero or one HLA-A mismatch compared with those having two HLA-A mismatches. This beneficial effect on survival was equivalent to a reduction of ischemic time of 168 minutes. Conclusions: We observed a reduced incidence of BOS and a better survival rate in patients well-matched at the HLA-A locus, associated with an opposite effect of an enhanced ischemic time. This suggests that graft ischemic time should be taken into account in future studies of prospective HLA matching in LTx.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.